Pseudoprogression in glioma management
During the treatment of malignant gliomas (e.g., glioblastomas) using combined chemoradiotherapy (specifically with temozolomide), the phenomenon of pseudoprogression frequently occurs. Essentially, this is a massive inflammatory response of the brain tissue to the administered treatment.
On contrast-enhanced T1-weighted MRI scans, the process develops as follows:
- Baseline (pre-treatment): a tumor with heterogeneous ring-like contrast enhancement is identified.
- 6 weeks post-treatment: false radiological worsening is observed. The zone of contrast agent enhancement increases, and concomitant perifocal edema also progresses.
- At 16 weeks up to 6 months: the edema and contrast enhancement zone begin to gradually and spontaneously decrease, leaving only a small residual area.
The key point is that the regression of these alarming changes occurs without changing the treatment regimen. Furthermore, the development of pseudoprogression is considered a sign of a favorable outcome (favourable outcome).
Pseudoresponse phenomenon
Unlike pseudoprogression, which mimics deterioration, pseudoresponse creates a false illusion of recovery. This phenomenon is characteristic of patients receiving anti-angiogenic therapy (vascular endothelial growth factor inhibitors — anti-VEGF).
On MRI, the picture changes paradoxically:
- Initially, the tumor consists of an enhancing component and a non-enhancing infiltrative zone, hyperintense on FLAIR sequences.
- After 6 weeks of anti-angiogenic therapy, T1-weighted contrast-enhanced MRI shows a pronounced decrease in contrast enhancement and reduction of edema. However, FLAIR images reveal thickening of adjacent structures (e.g., the corpus callosum).
- After 16 weeks, enhancement remains minimal, but the non-enhancing infiltrative part continues to grow actively.
The clinical significance of this phenomenon is enormous: visible improvement on T1 with gadolinium does not reflect true tumor control. Infiltrative growth continues covertly.
Differential diagnosis of radiation necrosis and recurrence
Distinguishing radiation necrosis from true tumor recurrence is extremely challenging, as both conditions can manifest with ring-like contrast enhancement. Advanced neuroimaging methods are used for differential diagnosis:
- Radiation necrosis (Radiation necrosis):
- Characterized by low glucose metabolism on PET (reduced fluorodeoxyglucose uptake).
- Perfusion maps show low relative cerebral blood volume (low rCBV).
- Over time (e.g., at 5 months), the contrast enhancement zone may resolve almost completely.
- Tumour recurrence (Tumour recurrence):
- Demonstrates high glucose uptake on PET and high blood flow (rCBV).
- DCE-perfusion (Dynamic Contrast-Enhanced) reveals a significantly higher maximum slope of the contrast accumulation curve compared to necrosis.
- Apparent diffusion coefficient (ADC) values in recurrence foci are significantly lower. This is due to the high cellular density (cellular density) of the growing malignant tissue, which restricts the movement of water molecules.
Advanced technologies and biopsy navigation
Stereotactic biopsy is frequently used for definitive histological verification. PWI (perfusion), DWI (diffusion), and MRS (MR spectroscopy) methods are used for precise navigation — allowing the needle to be guided to areas with maximum angiogenesis, highest cellular density, and peak metabolic activity.
Among promising novel techniques, CEST (chemical exchange saturation transfer) stands out. This method identifies molecular interactions of tissue-bound water protons (e.g., amide proton transfer — APT-CEST). It reflects tumor metabolism and holds great potential in differentiating malignant gliomas from slow-growing lesions. The future of diagnostics in this field is linked with radiogenomics, texture analysis, and the implementation of machine learning algorithms.
Briefly: answers to topical questions
Which specific metabolites are evaluated using MR spectroscopy (MRS) to differentiate recurrence from necrosis?
Proton MR spectroscopy evaluates the following metabolites:
- N-acetylaspartate (NAA) — present predominantly in neurons; reduction or loss of its peak is associated with neuronal death.
- Choline-containing molecules (Cho) — involved in lipid biosynthesis; the choline peak is a dominant feature in the spectra of most tumors.
- Creatine (Cr) and phosphocreatine (PCr).
The frequency shift of the peak allows identification of the molecule, while the area under the peak curve indicates its concentration relative to a standard.
What criteria are used for standardized neuroimaging assessment of glioma treatment response (RANO criteria)?
For standardized evaluation of the dynamics of primary central nervous system tumors, RANO criteria (Response Assessment in Neuro-Oncology) are applied.
Treatment efficacy is evaluated regularly using brain and/or spinal cord MRI, with and without contrast. The frequency of MRI scans depends on the histological diagnosis and the patient's treatment stage. Specific measured parameters of the RANO criteria are not detailed in the cited sources.
For differential diagnosis of recurrence, remember the "Rule of Three Highs" for true tumor growth: High metabolism (PET), High blood flow (rCBV), and High cellular density (low ADC).
Class and exam questions
How long after treatment does pseudoprogression typically develop?
The false radiological worsening typical of pseudoprogression manifests most prominently approximately 6 weeks after chemoradiotherapy.
Why does the ADC value decrease on diffusion MRI in glioblastoma recurrence?
The decrease in the apparent diffusion coefficient (ADC) in recurrence is due to the high cellular density of the malignant neoplasm, which physically restricts the diffusion of water molecules in the tissue.
What is the main danger of the pseudoresponse phenomenon in tumor treatment?
During anti-angiogenic therapy, T1-contrast-enhanced MRI scans may show false improvement (reduced enhancement). Meanwhile, FLAIR imaging reveals that the covert infiltrative tumor growth has not been halted.
What else to study on this topic
- Radiogenomics in neuro-oncology: non-invasive determination of molecular subtypes.
- Glioneuronal tumors: imaging semiotics of gangliogliomas and gangliocytomas.
- Dysembryoplastic neuroepithelial tumor (DNT) and its association with focal cortical dysplasia.
- Primary and secondary CNS lymphoma: contrast enhancement patterns and diffusion restrictions.
- Application of MR spectroscopy (MRS) for assessing choline and lipid metabolic peaks.
Master the entire topic in the "Diagnostic Radiology" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Pseudoprogression and radiation necrosis" and 2,199 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 10 video lessons on the subject
Other topics in the Neuroimaging section
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.